ClinicalTrials.gg
Not yet recruitingNCT07939399Updated Nov 16, 2026

A Study of V951A in Healthy Participants (V951A-001)

A Phase 1 interventional study of V951A and Placebo in Healthy Volunteers, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
252
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Study summary

This early study is testing an investigational vaccine called V951A. This study is looking for healthy volunteers. The main goals are to find out if the vaccine is safe, how well the human body handles different doses of it, and if it helps the body build immune defenses.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Good General Health: Is in good health as determined by medical history, physical examination, vital signs, and clinical laboratory evaluations prior to study dosing.
  • (BMI): Has a BMI within the range of 18.0 to 32.0 kg/m² (inclusive) at the time of screening.
  • Vaccine Naïveté: Has never previously received any or licensed vaccine targeting the same disease or class as V951A.
  • Study Compliance: Understands the study procedures, agrees to stay in contact with the clinic site, and is willing and able to comply with all trial requirements (including maintaining a daily symptom diary card)

Exclusion criteria

Exclusion Criteria:

  • Active or Unstable Illness: Has any ongoing, unstable, or symptomatic acute or chronic medical condition requiring active medical care or hospitalization within the past year (e.g., uncontrolled cardiovascular, respiratory, hepatic, or renal diseases).
  • Immunological Disorders: Has a known or suspected history of primary or acquired immunodeficiency, an active disease requiring systemic therapy (including oral ) within the past 6 months, or a positive screening test for , , or .
  • Severe Allergies: Has a history of severe allergic reactions (e.g., anaphylaxis) to any vaccine or vaccine component.
  • Recent Vaccines: Has received any licensed live or inactive vaccine within 4 weeks prior to the first study dose, or plans to receive any other vaccine during the study period.
  • History: Has an active history of cancer (malignancy) within the past 5 to 10 years, except for successfully treated localized non-melanoma skin cancer.
  • Blood Donation: Has donated blood or blood products (>450 mL) within 30 days prior to receiving the first dose of study vaccine.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
252 participants (estimated)

Study arms

  • Experimental
    V951A Group A

    Healthy younger adult participants (typically aged 18 to 49) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in a younger population.

    Biological: V951A

  • Experimental
    V951A Group B

    Healthy older adult participants (typically aged 50 and older) who will receive active injections of the investigational vaccine V951A. This group is evaluated to determine the vaccine's safety, tolerability, and early immune response in an older population.

    Biological: V951A

  • Placebo comparator
    Placebo

    Healthy adult participants who will receive placebo injections containing no active vaccine. This group acts as a comparator to help researchers safely evaluate the effects of the active investigational vaccine.

    Other: Placebo

Interventions

  • BiologicalV951A

    Administered via intramuscular injection.

  • OtherPlacebo

    Administered via intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Solicited Injection-Site Adverse Events (AE)

    An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited injection-site AEs are predetermined local reactions at the injection site (such as pain/tenderness, erythema/redness, and swelling) recorded on the participant's electronic diary card.

    Time frame: Up to 7 days after each vaccination

  2. Percentage of Participants with Solicited Systemic AE

    An AE is defined as any untoward medical occurrence in a clinical database participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Solicited systemic AEs are predetermined body-wide reactions (such as headache, fever, fatigue, myalgia/muscle pain, and arthralgia/joint pain) recorded on the participant's electronic diary card.

    Time frame: Up to 7 days after each vaccination

  3. Percentage of Participants with Immediate Post-Vaccination AEs

    This measures specific body-wide side effects monitored closely (typically fever, headache, fatigue, muscle pain, and joint pain).

    Time frame: Up to 30 minutes after each immunization

  4. Percentage of Participants with Unsolicited AEs

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. Unsolicited AEs are any unexpected, non-predetermined medical events reported by the participant that are not specifically listed on the daily diary card.

    Time frame: Up to 28 days after each immunization

  5. Percentage of Participants with Serious Adverse Events (SAEs)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A Serious Adverse Event (SAE) is any AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event that may jeopardize the participant.

    Time frame: Up to approximately 18 months

  6. Percentage of Participants with Medically Attended AEs (MAAEs)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. A MAAE is defined as any AE that results in an unscheduled visit to a healthcare professional (such as a physician's office, clinic, or emergency room) for medical evaluation or treatment.

    Time frame: Up to approximately 18 months

  7. Percentage of Participants with Adverse Events of Special Interest (AESIs)

    An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related. An AESI is a noteworthy medical event of clinical interest (such as a severe allergic reaction or specific neurological event) that has been designated for expedited tracking and continuous safety surveillance within this vaccine clinical program.

    Time frame: Up to approximately 18 months

Secondary outcomes

  1. Geometric Mean Concentration (GMC) of V951A-Specific Antibodies

    This measures the average amount of antibodies produced by the participants' immune systems in response to the V951A vaccine. The concentration is determined using a specialized laboratory assay.

    Time frame: At designated time points and up to up to approximately 18 months

  2. Percentage of Participants Achieving Seroconversion to V951A

    Seroconversion is defined as a transition from a seronegative baseline (undetectable antibody levels prior to vaccination) to a seropositive post-vaccination status, or a pre-defined multi-fold increase (typically ≥ 4-fold) in antibody concentrations from baseline to post-vaccination as determined by a specialized laboratory assay.

    Time frame: At designated time points and up to up to approximately 18 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Aug 2029, 32 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Aug 6, 2029
CompletionEst.
Aug 6, 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939399
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Aug 6, 2029 (estimated)
Completion
Aug 6, 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion